Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid

被引:10
作者
Bonnefoix, T
Gressin, R
Jacrot, M
Perron, P
Swiercz, P
Chaffanjon, P
Sotto, JJ
机构
[1] Institut Albert Bonniot, Rond-Point de la Chantourne
[2] Service d'Hématologie, Grenoble
[3] Service de Chirurgie Thoracique, CHU Michailon, Grenoble
关键词
B lymphoma; cytokines; interferon alpha; all-trans-retinoic acid; proliferation;
D O I
10.3109/10428199709042507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the potential of ten cytokines (IL2, IL3, IL4, IL6, IL10, IL13, G-CSF, GM-CSF, interferon alpha, interferon gamma) and all-trans-retinoic acid to modulate the spontaneous proliferative response in vitro of purified B-non Hodgkin's lymphoma cells of various histological subtypes. 19 malignant lymph nodes were studied. In each case the growth could be influenced by several of these modulators. Cytokines most often implicated were interferon gamma (14/19 cases, 73.7%), IL4 (13/19 cases, 68.4%), interferon alpha (12/19 cases, 63.1%). IL2 (9/19 cases, 47.3%), IL6, IL10, IL13 and ATRA were less frequently involved (6/19 cases, 31.6%) and hematopoietic growth factors (IL3, GM-CSF, G-CSF) were rarely implicated (2/19 cases, 10.5%). The values of growth stimulation ranged from a 1.1-fold to a 6.1-fold increase, and the values of growth inhibition ranged from 15% to 98%. Each cytokine could be either inhibitory or stimulatory depending on the sample analyzed, and no relationship could be found with the histological subtype. Two notable exceptions were IL2, displaying exclusively a positive effect, and ATRA displaying exclusively a negative effect. Overall, these results may have strong implications for future clinical studies using cytokines in the treatment of lymphomas. Ideally, the pattern of in vitro growth response to cytokines or ATRA should be determined individually before undertaking any cytokine treatment.
引用
收藏
页码:169 / 178
页数:10
相关论文
共 33 条
[1]   INTERLEUKIN-2 LYMPHOKINE-ACTIVATED KILLER-CELL THERAPY OF NON-HODGKINS-LYMPHOMA AND HODGKINS-DISEASE [J].
BERNSTEIN, ZP ;
VAICKUS, L ;
FRIEDMAN, N ;
GOLDROSEN, MH ;
WATANABE, H ;
RAHMAN, R ;
ARBUCK, SG ;
SWEENEY, J ;
VESPER, D ;
HENDERSON, ED ;
ZEFFREN, J ;
DENNIN, RA ;
LEVITT, D ;
FOON, KA .
JOURNAL OF IMMUNOTHERAPY, 1991, 10 (02) :141-146
[2]   CHARACTERIZATION OF A NEW IL-6-DEPENDENT HUMAN B-LYMPHOMA CELL-LINE IN LONG-TERM CULTURE [J].
BOCK, GH ;
LONG, CA ;
RILEY, ML ;
WHITE, JD ;
KURMAN, CC ;
FLEISHER, TA ;
TSOKOS, M ;
BROWN, M ;
SERBOUSEK, D ;
SCHWIETERMANN, WD ;
NELSON, DL .
CYTOKINE, 1993, 5 (05) :480-489
[3]   GROWTH-INHIBITION OF HUMAN-BREAST CARCINOMA AND LEUKEMIA LYMPHOMA CELL-LINES BY RECOMBINANT INTERFERON-BETA-2 [J].
CHEN, L ;
MORY, Y ;
ZILBERSTEIN, A ;
REVEL, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (21) :8037-8041
[4]   INTERLEUKIN-3 IS A GROWTH-FACTOR FOR HUMAN FOLLICULAR B-CELL LYMPHOMA [J].
CLAYBERGER, C ;
LUNAFINEMAN, S ;
LEE, JE ;
PILLAI, A ;
CAMPBELL, M ;
LEVY, R ;
KRENSKY, AM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :371-376
[5]  
DEFRANCE T, 1992, BLOOD, V79, P990
[6]   GROWTH FACTOR-MEDIATED PROLIFERATION IN B-CELL NON-HODGKINS LYMPHOMAS [J].
FORD, RJ ;
KOUTTAB, NM ;
SAHASRABUDDHE, CG ;
DAVIS, FM ;
MEHTA, SR .
BLOOD, 1985, 65 (06) :1335-1341
[7]  
FORD RJ, 1990, BLOOD, V75, P1311
[8]   LYMPHOTOXIN ACTS AS AN AUTOCRINE GROWTH-FACTOR FOR EPSTEIN-BARR VIRUS-TRANSFORMED B-CELLS AND DIFFERENTIATED BURKITT-LYMPHOMA CELL-LINES [J].
GIBBONS, DL ;
ROWE, M ;
COPE, AP ;
FELDMANN, M ;
BRENNAN, FM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (08) :1879-1885
[9]  
GISSELBRECHT C, 1994, BLOOD, V83, P2081
[10]  
GRIGNANI F, 1994, BLOOD, V83, P10